nVerses Capital LLC Purchases 2,100 Shares of CareDx, Inc (NASDAQ:CDNA)

nVerses Capital LLC increased its position in CareDx, Inc (NASDAQ:CDNA) by 175.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,300 shares of the company’s stock after acquiring an additional 2,100 shares during the quarter. nVerses Capital LLC’s holdings in CareDx were worth $103,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC increased its holdings in shares of CareDx by 1,021.8% during the 2nd quarter. GAMMA Investing LLC now owns 2,210 shares of the company’s stock worth $34,000 after purchasing an additional 2,013 shares during the period. Plato Investment Management Ltd bought a new position in shares of CareDx during the 2nd quarter worth about $62,000. Meeder Asset Management Inc. bought a new position in shares of CareDx during the 2nd quarter worth about $142,000. Allspring Global Investments Holdings LLC increased its holdings in shares of CareDx by 10,267.2% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 18,661 shares of the company’s stock worth $198,000 after purchasing an additional 18,481 shares during the period. Finally, Creative Planning bought a new position in shares of CareDx during the 3rd quarter worth about $204,000.

Insider Transactions at CareDx

In other news, insider Alexander L. Johnson sold 21,557 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $32.58, for a total transaction of $702,327.06. Following the transaction, the insider now directly owns 284,983 shares in the company, valued at approximately $9,284,746.14. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Peter Maag sold 35,552 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $33.04, for a total transaction of $1,174,638.08. Following the transaction, the director now directly owns 330,024 shares in the company, valued at approximately $10,903,992.96. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Alexander L. Johnson sold 21,557 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $32.58, for a total transaction of $702,327.06. Following the transaction, the insider now owns 284,983 shares in the company, valued at $9,284,746.14. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 91,340 shares of company stock worth $3,025,415. Corporate insiders own 4.20% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on CDNA shares. Wells Fargo & Company started coverage on shares of CareDx in a report on Tuesday, August 27th. They set an “underweight” rating and a $28.00 price objective on the stock. Craig Hallum upped their target price on shares of CareDx from $22.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. BTIG Research raised shares of CareDx from a “neutral” rating to a “buy” rating and set a $40.00 target price on the stock in a research note on Monday, August 19th. HC Wainwright reissued a “neutral” rating on shares of CareDx in a research note on Thursday, August 1st. Finally, The Goldman Sachs Group upped their target price on shares of CareDx from $26.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, CareDx currently has a consensus rating of “Moderate Buy” and an average price target of $30.60.

CareDx Stock Down 2.0 %

NASDAQ:CDNA opened at $23.98 on Monday. The firm has a market cap of $1.25 billion, a PE ratio of -7.01 and a beta of 1.77. CareDx, Inc has a 12 month low of $4.80 and a 12 month high of $34.84. The company’s 50-day moving average price is $29.62 and its two-hundred day moving average price is $19.78.

CareDx (NASDAQ:CDNA) last released its quarterly earnings results on Wednesday, July 31st. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.37. The firm had revenue of $92.27 million for the quarter, compared to analyst estimates of $67.20 million. CareDx had a negative net margin of 53.73% and a negative return on equity of 53.65%. On average, research analysts expect that CareDx, Inc will post -0.84 EPS for the current fiscal year.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.